Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Frontiers in Oncology

Oncology

Augusto Kreling Medeiros¹  Raíssa Pierri Carvalho¹  Felipe Marques da Costa¹  Caio Abner Leite¹  Fabio Augusto Schutz¹  William Nassib William² 

[1] Department of Clinical Oncology, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil;Department of Clinical Oncology, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil;Oncoclinicas, São Paulo, Brazil;

关键词: lung adenocarcinoma;    RET;    MET;    selpercatinib;    capmatinib;   

DOI  :  10.3389/fonc.2023.1264231

 received in 2023-07-20, accepted in 2023-09-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary RET mutations, or in 5% via MET amplification. Co-inhibition of RET and MET is a compelling strategy for overcoming MET-dependent resistance to RET inhibitors and potentially other inhibitors. To our knowledge, this is the first report of a novel ISOC1-RET fusion lung cancer with a durable complete response to selpercatinib, with resistance via MET amplification, which was overcome by the successful combination of selpercatinib and capmatinib.

【 授权许可】

Unknown   
Copyright © 2023 Leite, Carvalho, da Costa, Medeiros, Schutz and William